Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Dedicated

- PMLiVE

AstraZeneca’s Imfinzi regimen approved by MHRA to treat resectable lung cancer

The drug is now approved in Great Britain to treat both resectable and unresectable NSCLC

- PMLiVE

J&J and Legend share positive late-stage results for Carvykti in multiple myeloma

More than 35,000 new cases of the blood cancer are expected to be diagnosed in the US this year

- PMLiVE

WHO publishes new toolkit to improve services for neurological disorders

Neurological conditions such as dementia and stroke were responsible for more than three billion cases globally in 2021

- PMLiVE

Why a LinkedIn short video feed is so exciting for healthcare comms

LinkedIn has confirmed that it’s currently experimenting with a short video feed, TikTok-style. This has rather split opinion online, with some seeing it as a mix that won’t work, while...

Wallace Health

- PMLiVE

Reaching Women Where They’re At: Setting Up a Safe Space for HIV Prevention Conversations

“I always enjoyed solving problems and putting puzzles together,” says Harmony Garges, MD, CMO at ViiV Healthcare and a pediatric infectious disease specialist. “So for me, infectious disease was a...

Medscape Education

- PMLiVE

The MM+M Agency 100 report: Oxford PharmaGenesis is recognized as an industry leader for the fourth year running

For the fourth year running, media brand Medical Marketing and Media (MM+M) has listed Oxford PharmaGenesis in its Agency 100 report – the annual definitive ‘who’s who’ ranking of the...

Oxford PharmaGenesis

- PMLiVE

AstraZeneca’s Tagrisso combination approved by EC as first-line lung cancer treatment

Non-small cell lung cancer accounts for up to 85% of all lung cancer diagnoses

- PMLiVE

J&J’s multidrug-resistant TB treatment Sirturo granted full EC and FDA approvals

An estimated 410,000 people globally developed multidrug- or rifampicin-resistant TB in 2022

- PMLiVE

LEO Pharma, Allergy UK and CHE Taskforce survey reveals burden of chronic hand eczema

The painful inflammatory skin condition, hand eczema, affects up to 14% of the UK population

- PMLiVE

Study identifies thousands of high-risk cancer gene variants and potential therapeutic target

Patients with inherited variants of the BAP1 gene have a 50% increased risk of developing certain cancers

- PMLiVE

Amgen’s Uplizna shown to improve pain and quality of life in attack-free NMOSD patients

The rare autoimmune disease is estimated to affect approximately 6,000 adults in the US

- PMLiVE

Emotive announces brand evolution

The agency’s refreshed visual identity has been launched alongside a new website

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links